Vol.

No.

November 19, 2021Nov 19, 2021

DOWNLOAD THE PDF

Tom Loughran tells us how he got UVA over the hump to comprehensive designation

Cover Story

Conversation with The Cancer Letter

Tom Loughran tells us how he got UVA over the hump to comprehensive designation

By Paul Goldberg

The University of Virginia has taken a long, circuitous path to NCI comprehensive cancer center designation, but it got there.

ACS CAN wages state-by-state battle to expand access to biomarker testing

By Alice Tracey

Guest Editorial Health Equity

To make clinical trials equitable, cancer groups evaluate restrictive eligibility criteria

By Julia Beaver, Thomas S. Uldrick, Gwynn Ison, Suanna S. Bruinooge, Caroline Schenkel and Edward S. Kim

Cancer History Project Conversation with The Cancer Letter Free

Patricia Ganz on how survivorship went from being an outlier to the mainstream

By Alexandria Carolan

Free In the Archives

Cancer researchers, including Nobel laureates, center directors, gather at Nixon Library to mark 50th anniversary of the National Cancer Act

In Brief

Bridget Oppong named deputy director of Ohio State’s Center for Cancer Health Equity

Mitchell Schnall to continue as ECOG-ACRIN Cancer Research Group co-chair

Helen Piwnica-Worms and Fabrice André are award winners for the 2021 San Antonio Breast Cancer Symposium

IU receives $2M gift supporting lung, pancreatic cancer research

IU team studying NF1 receives renewal for $11.4M SPORE

GeoVax and City of Hope to collaborate on City of Hope’s COVID-19 vaccine for immunocompromised patients

NEXT Oncology partners with Spanish Hospital System to open two phase I clinical trial centers

Clinical Roundup

ALA report: lung cancer survival has improved, but remains significantly lower for people of color

NCI-sponsored trial indicates optimal treatment sequence for BRAF V600 mutant metastatic melanoma

Michigan study finds lack of ATRA in hospitals

Yale study shows sotigalimab + Opdivo improves outcomes in advanced melanoma

Yale study finds rates of PSA testing for prostate cancer increased after revised national guidelines

Drugs & Targets

FDA approves Keytruda as adjuvant therapy for patients with RCC following nephrectomy

WVU gets FDA approval for clinical trial of drug to treat eye cancer ‘from the inside out’

Ribonexus, Pierre Fabre sign licensing agreement on small molecules targeting eIF4A

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 50 | Issue 41 - November 01, 2024